Uma Sinha

Dr Sinha. has extensive experience in discovery and preclinical development of small molecules involved in the pathogenesis of cardiovascular and inflammatory diseases. Dr. Sinha currently splits time between BridgeBio and Longevity Biotech. She is the former Chief Scientific Officer of Global Blood Therapeutics . Previously, she was Vice President, Head of Biology at Portola Pharmaceuticals and had held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. She is a co-inventor of andexanet alfa, a first in class recombinant protein currently awaiting FDA approval.